Edinburgh Research Explorer

Anatomical, histomorphological, and molecular classification of cholangiocarcinoma

Research output: Contribution to journalArticle

  • Tim Kendall
  • Joanne Verheij
  • Eugenio Gaudio
  • Matthias Evert
  • Maria Guido
  • Benjamin Goeppert
  • Guido Carpino

Related Edinburgh Organisations

Original languageEnglish
Pages (from-to)7-18
JournalLiver International
Volume39
Issue numbers1
Early online date18 Mar 2019
DOIs
Publication statusPublished - 31 May 2019

Abstract

Cholangiocarcinoma constitutes a heterogeneous group of malignancies that can emerge at any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar and distal based on its anatomical location. Histologically, conventional perihilar/distal cholangiocarcinomas are mucin-producing adenocarcinomas or papillary tumors; intrahepatic cholangiocarcinomas are more heterogeneous and can be sub-classified according to the level or size of the displayed bile duct. Cholangiocarcinoma develops through multistep carcinogenesis and is preceded by dysplastic and in situ lesions. Definition and clinical significance of precursor lesions, including biliary intraepithelial neoplasia, intraductal papillary neoplasms of the bile duct, intraductal tubulopapillary neoplasms and mucinous cystic neoplasm, are discussed in this review.
A main challenge in diagnosing cholangiocarcinoma is the fact that tumor tissue for histological examination is difficult to obtain. Thus, a major clinical obstacle is the establishment of the correct diagnosis at a tumor stage that is amenable to surgery which still represents the only curable therapeutic option. Current standards, methodology, and criteria for diagnosis are discussed. Cholangiocarcinoma represents a heterogeneous tumor with regard to molecular alterations. In intrahepatic subtype, mainly two distinctive morpho-molecular groups can currently be discriminated. Large-duct type intrahepatic cholangiocarcinoma shows a high mutation frequency of oncogenes and tumor suppressor genes, such as KRAS and TP53 while Isocitrate Dehydrogenase 1/2 mutations and Fibroblast Growth Factor Receptor 2-fusions are typically seen in small-duct type tumors. It is most important to ensure the separation of the given anatomical subtypes and to search for distinct subgroups within the subtypes on a molecular and morphological basis.

ID: 80543214